Rangeley Capital’s BridgeBio Pharma BBIO Stock Holding History

Rangeley Capital’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-5,000	Closed	-$382K	–	141
2025 Q4	$382K	Hold	5,000	–	–	0.32%	62
2025 Q3	$260K	Hold	5,000	–	–	0.22%	80
2025 Q2	$216K	Hold	5,000	–	–	0.26%	45
2025 Q1	$173K	Hold	5,000	–	–	0.19%	60
2024 Q4	$137K	Buy	+5,000	New	+$129K	0.12%	69

Other funds holding BBIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Rangeley Capital's BBIO Position: Q2 2025 in Review

Rangeley Capital sold out of BridgeBio Pharma (BBIO) in Q2 2025, closing a stake of 13,000 shares — an estimated $473K sold.

Rangeley Capital first reported a position in BBIO in Q4 2024 and held it in 2 quarters. The position peaked at $449K in Q1 2025. 359 funds tracked by Wall St. Rank hold BBIO as of Q2 2025.

Rangeley Capital reported no remaining BridgeBio Pharma position as of Q2 2025 after selling out during the quarter.
Rangeley Capital sold 13,000 BridgeBio Pharma shares in Q2 2025, an estimated $473K.
Rangeley Capital first reported a position in BridgeBio Pharma in Q4 2024 and held it in 2 quarters.
Rangeley Capital's BridgeBio Pharma position peaked at $449K in Q1 2025.
359 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2025.

Based on Rangeley Capital's 13F filing for Q2 2025, filed 14 Aug 2025.